Penambatan Molekuler Multi-Target Fitokimia dari Sereh (Cymbopogon Citratus) pada Protein Terkait Ketergantungan Nikotin dan Sinyal Neurovaskular
DOI:
https://doi.org/10.31539/f3960e91Abstract
This study aims to analyze the phytochemical composition, predictive pharmacokinetic properties, target networks, and molecular interactions of lemongrass essential oil compounds with proteins associated with nicotine dependence and neurovascular signaling. The essential oil was characterized using GC–MS. The compounds were screened via SwissADME and ProTox 3.0, while their targets were predicted using SwissTargetPrediction and Super-PRED. Genes related to nicotine dependence were retrieved from GeneCards and OMIM, and protein–protein interactions were mapped using STRING and Cytoscape. Thirteen selected compounds were docked against ABCB1, CHRNB2, MAOA, CHRNA3, HTR2A, and GRM5 using AutoDock Vina. A total of 15 compounds were identified, with citral (33.802%) and neral (24.625%) as the primary components. Fifty-five overlapping target candidates were identified, and six protein hubs were prioritized for docking. Most compounds exhibited favorable drug-likeness characteristics; all compounds, with the exception of β-cadinene, were predicted to be capable of crossing the blood-brain barrier. Anethole and isoamyl alcohol were excluded due to unfavorable toxicity or drug-likeness profiles. Binding affinities ranged from −3.615 to −8.033 kcal/mol. The strongest interactions were observed for α-cubebene–HTR2A, cis-β-copaene–CHRNB2, β-cadinene–MAOA, β-pinene–CHRNA3, copaene–ABCB1, and eugenol–GRM5, respectively. Lemongrass phytochemicals demonstrate a specific binding profile involving nicotinic, serotonergic, monoaminergic, and glutamatergic pathways, as well as the blood-brain barrier. These findings support further experimental validation to examine nicotine dependence, neurovascular signaling, and smoking-related vascular dysfunction.
Keyword: Cymbopogon Citratus, Lemongrass, Molecular Docking, Neurovascular Signaling, Nicotine Dependence, Nicotinic Acetylcholine Receptor.
References
Aly, O., Mekky, R. H., Pereira, F., Diab, Y. M., Tammam, M. A., & El-Demerdash, A. (2024). Deciphering the potential of Cymbopogon citratus (DC.) Stapf as an anti-obesity agent: Phytochemical profiling, in vivo evaluations and molecular docking studies. Food & Function, 15(24), 12146–12168. https://doi.org/10.1039/D4FO04602A
Baldassarri, S. R., Asch, R. H., Hillmer, A. T., Pietrzak, R. H., DellaGioia, N., Esterlis, I., & Davis, M. T. (2023). Nicotine use and metabotropic glutamate receptor 5 in individuals with major depressive and posttraumatic stress disorders. Chronic Stress, 7, 24705470231154842. https://doi.org/10.1177/24705470231154842
Chai, A. B., Callaghan, R., & Gelissen, I. C. (2022). Regulation of P-glycoprotein in the brain. International Journal of Molecular Sciences, 23(23), 14667. https://doi.org/10.3390/ijms232314667
Cortes-Torres, A. G., López-Castillo, G. N., Marín-Torres, J. L., Portillo-Reyes, R., Luna, F., Baca, B. E., Sandoval-Ramírez, J., & Carrasco-Carballo, A. (2023). Cymbopogon citratus essential oil: Extraction, GC-MS, phytochemical analysis, antioxidant activity, and in silico molecular docking for protein targets related to CNS. Current Issues in Molecular Biology, 45(6), 5164–5179. https://doi.org/10.3390/cimb45060328
Du, X., Zhang, M., Wang, S., Li, J., Zhang, J., & Liu, D. (2024). Ethnopharmacology, chemical composition and functions of Cymbopogon citratus. Chinese Herbal Medicines, 16(3), 358–374. https://doi.org/10.1016/j.chmed.2023.07.002
Evbuomwan, I. O., Alejolowo, O. O., Elebiyo, T. C., Nwonuma, C. O., Ojo, O. A., Edosomwan, E. U., et al. (2024). In silico modeling revealed phytomolecules derived from Cymbopogon citratus (DC.) leaf extract as promising candidates for malaria therapy. Journal of Biomolecular Structure and Dynamics, 42(1), 101–118. https://doi.org/10.1080/07391102.2023.2192799
Hong, S. W., Teesdale-Spittle, P., Page, R., & Truman, P. (2022). A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke. Neurotoxicology, 93, 163–172. https://doi.org/10.1016/j.neuro.2022.09.008
Jones, S. K., Wolf, B. J., Froeliger, B., Wallace, K., Carpenter, M. J., & Alberg, A. J. (2022). A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. Drug and Alcohol Dependence, 239, 109596. https://doi.org/10.1016/j.drugalcdep.2022.109596
Klein, J., Diaba-Nuhoho, P., Giebe, S., Brunssen, C., & Morawietz, H. (2023). Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products. Pflügers Archiv – European Journal of Physiology, 475(7), 835–844. https://doi.org/10.1007/s00424-023-02824-w
Paggi, J. M., Pandit, A., & Dror, R. O. (2024). The art and science of molecular docking. Annual Review of Biochemistry, 93, 389–410. https://doi.org/10.1146/annurev-biochem-030222-120000
Veliz Perez, A., Badea, M., & Gaman, E. L. (2026). Serotonin in cardiovascular disease: From pathophysiological insights to clinical utility. Diagnostics, 16(13), 2068. https://doi.org/10.3390/diagnostics16132068
Ren, J., Yang, T., Liu, H., Ma, P., Zhou, M., Li, J., et al. (2024). Metabotropic glutamate receptor 5 promotes blood-brain barrier recovery after traumatic brain injury. Experimental Neurology, 374, 114691. https://doi.org/10.1016/j.expneurol.2024.114691
Wills, L., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022). Neurobiological mechanisms of nicotine reward and aversion. Pharmacological Reviews, 74(1), 271–310. https://doi.org/10.1124/pharmrev.121.000299
World Health Organization. (2026). Tobacco and nicotine. World Health Organization.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Indah Nur Chomsy

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
